Table 6.

Parameters of mineral metabolism at baseline and study end (12 weeks) in study participants with serum 25-hydroxyvitamin D levels < 50 nmol/l at baseline (n = 39)

	Baseline visit		Study end		Treatment effect		p value
	Median	IQR	Median	IQR	Between-group differences with 95% CI
25-Hydroxyvitamin D (nmol/l)
Vitamin D (n = 19)	41	34–45	86	79–95	37	27 to 47	< 0.001
Placebo (n = 20)	41	37–44	54	42–62
PTH (pg/ml)
Vitamin D (n = 17)	49.3	35.7–65.5	45.4	30.6–66.1	− 2.7	− 10.0 to 4.6	0.452
Placebo (n = 19)	51.1	42.4–59.0	52.0	46.0–58.2
Serum calcium (mmol/l)
Vitamin D (n = 17)	2.37	2.34–2.44	2.36	2.32–2.38	− 0.1	− 0.1 to 0.1	0.969
Placebo (n = 19)	2.34	2.30–2.39	2.33	2.27–2.39
Urine calcium (mmol/l)
Vitamin D (n = 17)	2.57	1.19–3.88	1.43	1.11–2.45	− 1.26	− 2.60 to 0.07	0.062
Placebo (n = 19)	3.19	2.69–4.44	3.36	2.15–5.59

Data are shown as medians and interquartile range. Treatment effects with 95% confidence interval and p values were calculated by ANCOVA for group differences at follow-up with adjustment for baseline values